Other languages Baudax Bio, Inc.

Equities

Delayed OTC Markets Other stock markets 09:55:26 2024-04-25 am EDT			5-day change	1st Jan Change
0.0105 ^USD	0.00%		-4.55%	-52.27%

Feb. 22	Baudax Bio, Inc. Filed for Bankruptcy	CI
2023	Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Baudax Bio, Inc. Filed for Bankruptcy	Feb. 21
Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20
Baudax Bio, Inc. to Initiate TI-168 Clinical Development	23-10-18
Sector Update: Health Care Stocks Advancing in Late Afternoon Trading	23-10-06
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-10-06
Baudax Bio Appoints Natalie McAndrew as Interim Finance Chief	23-10-06
Baudax Bio, Inc. Announces Board Changes	23-10-06
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	23-09-29
Top Premarket Decliners	23-09-29
Baudax Bio, Inc. Announces Orphan Drug Designation Granted by U.S. Fda for Ti-168 for the Treatment of Hemophilia A with Inhibitors	23-09-29
Sector Update: Health Care Stocks Rising in Late Afternoon Trading	23-09-28
Sector Update: Health Care	23-09-28
Top Midday Gainers	23-09-28
Wall Street Set to Open Flat; Q2 GDP Rises 2.1%; Jobless Claims Lower Than Expected	23-09-28
Baudax Bio Files Registration Statement on Behalf of Selling Stockholder	23-09-22
Baudax Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16
Baudax Bio, Inc. Appoints Yong Chan Kim as A Member of the Board	23-07-05
Sector Update: Health Care Stocks Advancing in Late Trading	23-06-30
Sector Update: Health Care	23-06-30
Baudax Bio Shares More Than Double After Purchase of Cell Therapy Developer TeraImmune	23-06-30

No results for this search